<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01385917</url>
  </required_header>
  <id_info>
    <org_study_id>GHN007.10</org_study_id>
    <nct_id>NCT01385917</nct_id>
  </id_info>
  <brief_title>Observational Study of Patients With Duchenne Muscular Dystrophy Theoretically Treatable With Exon 53 Skipping</brief_title>
  <acronym>pre U7-53</acronym>
  <official_title>Study of Clinical and Radiological Changes in Patients With Duchenne Muscular Dystrophy Theoretically Treatable With Exon 53 Skipping</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genethon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute of Myology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Genethon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PreU7-53 is a natural history study. The objective is to monitor the clinical and
      radiological course of upper limb muscle impairment in patients with Duchenne Muscular
      Dystrophy (DMD), potentially treatable with AAV-mediated exon 53 skipping.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PreU7-53 is a natural history study</measure>
    <time_frame>Every year</time_frame>
    <description>The objective is to monitor the clinical and radiological course of upper limb muscle impairment in patients with DMD, potentially treatable with AAV-mediated exon 53 skipping.</description>
  </primary_outcome>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Total blood count with differential leukocyte count Assay of immunoglobulins and the various
      sub-classes (IgG, IgM, IgA, IgE) Test for immunisation against all AAV serotypes Serum urea,
      creatinine, AST/ALT , GammaGT, bilirubin, CK, alkalin phosphatase
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with theoretically exon 53 skipping-treatable DMD
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Duchenne muscular dystrophy confirmed by at least genetic testing,
             theoretically treatable by exon 53 skipping.

          -  Age between â‰¥ 12 and &lt;20 years old.

          -  Non ambulant patients (i;e; inability to walk more than 10 meters without any of
             assistance).

          -  Patients covered by a national health insurance scheme.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Patient incapable of sitting upright in a wheelchair for at least one hour.

          -  Patients with severe intellectual impairment preventing them from fully understanding
             the exercises to be performed.

          -  Recent (less than 6 months ago) upper limb surgery or trauma This criteria is however
             no definitive. Patients who have undergone upper limb surgery or trauma may
             nonetheless be enrolled once the 6 month period is over.

          -  Known immune deficiency.

          -  Contraindications to NMR exams
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent SERVAIS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Myology Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Myology Institute</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Servais, MD</last_name>
      <phone>01 42 16 66 47</phone>
      <email>l.servais@institut-myologie.org</email>
    </contact>
    <investigator>
      <last_name>Laurent SERVAIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great ormond Street Hospital &amp; University College London Hospital</name>
      <address>
        <city>London</city>
        <zip>WC1N 1EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Muntoni, Pr, HD</last_name>
      <phone>+44 1 02079052111</phone>
      <email>f.muntoni@ich.ucl.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2011</study_first_submitted>
  <study_first_submitted_qc>June 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2011</study_first_posted>
  <last_update_submitted>April 11, 2016</last_update_submitted>
  <last_update_submitted_qc>April 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duchenne Muscular Dystrophy</keyword>
  <keyword>strength and function tests</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

